IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 55.832
AS - Asia 9.071
EU - Europa 6.544
SA - Sud America 1.256
AF - Africa 91
OC - Oceania 40
Continente sconosciuto - Info sul continente non disponibili 27
Totale 72.861
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 55.591
SG - Singapore 3.962
CN - Cina 2.089
BR - Brasile 1.048
UA - Ucraina 977
RU - Federazione Russa 939
IT - Italia 890
HK - Hong Kong 861
IE - Irlanda 768
DE - Germania 686
VN - Vietnam 650
FR - Francia 557
KR - Corea 556
PL - Polonia 422
GB - Regno Unito 399
FI - Finlandia 360
BD - Bangladesh 245
JP - Giappone 224
SE - Svezia 203
CA - Canada 135
NL - Olanda 131
IN - India 90
ID - Indonesia 72
AR - Argentina 66
MX - Messico 52
IQ - Iraq 48
ES - Italia 43
AT - Austria 35
EC - Ecuador 30
MY - Malesia 30
CO - Colombia 29
PK - Pakistan 29
AU - Australia 28
BE - Belgio 27
CL - Cile 26
TR - Turchia 26
UZ - Uzbekistan 25
PH - Filippine 24
ZA - Sudafrica 23
EG - Egitto 18
MA - Marocco 17
PE - Perù 17
SA - Arabia Saudita 17
IL - Israele 16
TH - Thailandia 16
A2 - ???statistics.table.value.countryCode.A2??? 15
PY - Paraguay 15
PT - Portogallo 14
VE - Venezuela 14
EU - Europa 12
GR - Grecia 12
JO - Giordania 12
NZ - Nuova Zelanda 12
AE - Emirati Arabi Uniti 11
CR - Costa Rica 11
CH - Svizzera 9
IR - Iran 9
TW - Taiwan 9
RO - Romania 8
CZ - Repubblica Ceca 7
KE - Kenya 7
LT - Lituania 7
NP - Nepal 7
TT - Trinidad e Tobago 7
AL - Albania 6
AZ - Azerbaigian 6
ET - Etiopia 6
JM - Giamaica 6
KZ - Kazakistan 6
NO - Norvegia 6
BO - Bolivia 5
DZ - Algeria 5
HU - Ungheria 5
MK - Macedonia 5
PA - Panama 5
TN - Tunisia 5
UY - Uruguay 5
BG - Bulgaria 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
EE - Estonia 4
GT - Guatemala 4
LB - Libano 4
MD - Moldavia 4
RS - Serbia 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BH - Bahrain 3
KH - Cambogia 3
LK - Sri Lanka 3
LV - Lettonia 3
NI - Nicaragua 3
OM - Oman 3
PR - Porto Rico 3
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
BW - Botswana 2
CI - Costa d'Avorio 2
DM - Dominica 2
Totale 72.840
Salva come PNG Salva come JPEG
Città #
Woodbridge 12.783
Wilmington 12.542
Houston 12.267
Fairfield 2.728
Singapore 1.979
Ann Arbor 1.724
Ashburn 1.549
Seattle 1.157
San Jose 990
Chandler 910
Cambridge 889
Hong Kong 852
Jacksonville 835
Dublin 687
Beijing 615
Medford 531
Dearborn 461
Hangzhou 424
Kraków 403
Santa Clara 358
New York 303
Council Bluffs 291
The Dalles 269
Ho Chi Minh City 240
Lawrence 238
Los Angeles 220
Rome 201
Tokyo 186
Lauterbourg 169
Zhengzhou 164
Hanoi 155
Helsinki 153
Buffalo 145
San Diego 140
Moscow 127
Dallas 121
Menlo Park 120
Chicago 85
São Paulo 84
Mülheim 83
Milan 80
Colorado Springs 76
Naples 71
Monte Vista 57
Redwood City 57
Norwalk 55
London 52
Cardiff 47
Shanghai 47
Boardman 46
Mountain View 46
Redondo Beach 45
Toronto 45
Jakarta 42
Verona 42
Columbus 40
Detroit 40
Guangzhou 40
Hefei 39
San Mateo 37
Phoenix 35
Nanjing 34
Rio de Janeiro 32
University Park 31
Belo Horizonte 29
Brooklyn 28
Nuremberg 28
Palo Alto 28
San Francisco 28
Falls Church 27
Kunming 27
Orem 27
Montreal 26
Brussels 25
Da Nang 25
Munich 25
Atlanta 24
Frankfurt am Main 24
Denver 23
Jinan 22
Saint Petersburg 22
Stockholm 20
Tashkent 20
Haiphong 19
Brasília 18
Mexico City 18
Curitiba 17
Redmond 17
Charlotte 16
Poplar 16
Zaltbommel 16
Kuala Lumpur 15
Manchester 15
Warsaw 15
Amsterdam 14
Baghdad 14
Boston 14
Chengdu 14
Chennai 14
Salvador 14
Totale 60.058
Salva come PNG Salva come JPEG
Nome #
β2-Agonist Therapy in Lung Disease 542
An update on the pharmacotherapeutic management of lower respiratory tract infections 528
A systems medicine clinical platform for understanding and managing non- communicable diseases 515
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 513
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 510
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 509
Interaction between corticosteroids and muscarinic antagonists in human airways 503
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 499
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 490
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 489
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 485
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 485
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 485
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 484
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. 483
Asthma and comorbid medical illness. 483
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 480
Airflow obstruction: Is it asthma or is it COPD? 480
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 479
Optimizing drug delivery in COPD: The role of inhaler devices 479
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 478
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 475
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 469
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 466
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 464
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 464
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 460
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 459
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 455
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 452
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 450
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 448
Umeclidinium for the treatment of chronic obstructive pulmonary disease 447
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 446
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 446
Metabolic syndrome and risk of pulmonary involvement 445
The prevalence of asthma and COPD in Italy: a practice-based study 443
Tiotropium formulations and safety: a network meta-analysis 443
Asthma and comorbid medical illness 441
Role of muscarinic antagonists in asthma therapy 440
Bronchodilator therapy for chronic cough 438
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 435
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 433
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 433
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 432
The Challenges of Precision Medicine in COPD 431
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 430
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 430
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 429
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 429
New Treatments for COPD in the Elderly 428
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 425
The effect of indacaterol during an acute exacerbation of COPD 424
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 424
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 423
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD 422
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi 420
Translational study searching for synergy between glycopyrronium and indacaterol 420
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 420
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 418
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 418
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 417
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 417
Biomarkers of lung damage associated with tobacco smoke in induced sputum 417
Defining Phenotypes in COPD: An Aid to Personalized Healthcare 416
Comorbidities of asthma 416
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study 415
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 415
Adherence to COPD treatment: Myth and reality 415
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? 414
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 413
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives 407
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 406
Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure 405
Influence of ethnicity on response to asthma drugs 403
Treating systemic effects of COPD 401
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 400
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease 395
Indacaterol for the treatment of chronic obstructive pulmonary disease 395
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections 390
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics 390
The clinical use of regenerative therapy in COPD 390
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease 389
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients 389
Cardiovascular disease in patients with COPD 383
Diabetes mellitus among outpatients with COPD attending a university hospital. 375
Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism 373
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways 373
Biomarkers in COPD 368
Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved 367
Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: Forme-fruste of Churg-Strauss syndrome? 365
COPD diagnosis by a gas sensor array 365
An update on bronchodilators in Phase I and II clinical trials 362
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 362
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi 361
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids 361
Dual bronchodilation and exacerbations of COPD 360
Brain natriuretic peptide: Much more than a biomarker 359
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? 358
Novel glucocorticoid receptor agonists in the treatment of asthma 357
Totale 43.138
Salva come PNG Salva come JPEG
Categoria #
all - tutte 194.013
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 194.013
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.318 153 225 72 55 77 259 145 109 133 271 159 660
2022/20232.677 348 150 54 319 239 662 248 172 235 19 161 70
2023/2024889 192 27 68 11 85 212 61 38 16 34 12 133
2024/20255.845 217 1.349 622 318 184 206 510 321 538 548 565 467
2025/20269.902 649 503 1.208 739 889 317 1.273 1.156 1.385 713 617 453
2026/2027105 105 0 0 0 0 0 0 0 0 0 0 0
Totale 73.549